Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2078–2083. doi: 10.1128/aac.39.9.2078

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.

L E Gustavson 1, J F Kaiser 1, A L Edmonds 1, C S Locke 1, M L DeBartolo 1, D W Schneck 1
PMCID: PMC162884  PMID: 8540719

Abstract

This study was conducted to determine (i) the effect of omeprazole on steady-state concentrations of clarithromycin and 14-(R)-hydroxyclarithromycin in plasma and gastric mucosa, (ii) the effect of clarithromycin on steady-state concentrations of omeprazole in plasma, and (iii) the effect of clarithromycin on the suppression of gastric acid secretion by omeprazole. Twenty healthy, Helicobacter pylori-negative male subjects completed this three-period, double-blind, randomized crossover study. In period 1, all subjects received 40 mg of omeprazole each morning for 6 days. Twenty-four-hour gastric pH monitoring took place on days -1 and 6. Pharmacokinetic sampling took place on day 6. In periods 2 and 3, subjects were randomly assigned to receive either 40 mg of omeprazole or omeprazole placebo daily for 6 days plus clarithromycin (500 mg) every 8 h for 5 days with a single 500-mg dose on day 6. Gastric tissue and mucus samples were obtained via endoscopy on day 5. Gastric pH monitoring and pharmacokinetic sampling took place on day 6. Two-week washout intervals separated the three study periods. Clarithromycin increased mean omeprazole area under the concentration-time curve from 0 to 24 h from 3.3 +/- 2.0 to 6.3 +/- 4.5 micrograms.h/ml (P < 0.05) and harmonic mean half-life from 1.2 to 1.6 h (P < 0.05) but did not significantly alter the effect of omeprazole on gastric pH. Mean clarithromycin area under the concentration-time curve from 0 to 8 h increased from 22.9 +/- 5.5 (placebo) to 26.4 +/- 5.7 micrograms.h/ml (omeprazole) (P < 0.05) when clarithromycin was administered with omeprazole. Analysis of variance revealed that mean concentrations of clarithromycin in tissue and mucus were statistically significantly higher when clarithromycin was given with omeprazole than when clarithromycin was given with placebo (P <0.001). Mean maximum observed concentrations of clarithromycin in the gastric fundus increased from 20.8 +/- 7.6 (placebo) to 24.3 +/- 6.4 micrograms/g (omeprazole), and those in the gastric mucous from 4.2 +/- 7.7 placebo to 39.3 +/- 32.8 micrograms/g (omeprazole). Similar increases were observed for the 14-(R)-hydroxyclarithromycin. These results show that omeprazole increases concentrations of clarithromycin in gastric tissue and mucus and may provide a mechanism for synergy between clarithromycin ad omeprazole that explains the excellent eradication of H. pylori seen in clinical trials.

Full Text

The Full Text of this article is available as a PDF (213.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson T., Regårdh C. G., Dahl-Puustinen M. L., Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit. 1990 Jul;12(4):415–416. doi: 10.1097/00007691-199007000-00020. [DOI] [PubMed] [Google Scholar]
  2. Ateshkadi A., Lam N. P., Johnson C. A. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993 Jan;12(1):34–48. [PubMed] [Google Scholar]
  3. Chu S. Y., Deaton R., Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother. 1992 May;36(5):1147–1150. doi: 10.1128/aac.36.5.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chu S. Y., Sennello L. T., Sonders R. C. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1991 Nov 15;571(1-2):199–208. doi: 10.1016/0378-4347(91)80446-j. [DOI] [PubMed] [Google Scholar]
  5. Hazell S. L., Lee A., Brady L., Hennessy W. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis. 1986 Apr;153(4):658–663. doi: 10.1093/infdis/153.4.658. [DOI] [PubMed] [Google Scholar]
  6. Karol M. D., Granneman G. R., Alexander K. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):182–186. doi: 10.1016/0378-4347(95)00068-t. [DOI] [PubMed] [Google Scholar]
  7. Logan R. P., Gummett P. A., Hegarty B. T., Walker M. M., Baron J. H., Misiewicz J. J. Clarithromycin and omeprazole for Helicobacter pylori. Lancet. 1992 Jul 25;340(8813):239–239. doi: 10.1016/0140-6736(92)90502-t. [DOI] [PubMed] [Google Scholar]
  8. Logan R. P., Gummett P. A., Schaufelberger H. D., Greaves R. R., Mendelson G. M., Walker M. M., Thomas P. H., Baron J. H., Misiewicz J. J. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut. 1994 Mar;35(3):323–326. doi: 10.1136/gut.35.3.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Malanoski G. J., Eliopoulos G. M., Ferraro M. J., Moellering R. C., Jr Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):131–133. doi: 10.1007/BF01967591. [DOI] [PubMed] [Google Scholar]
  10. Nagate T., Numata K., Hanada K., Kondo I. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. J Clin Gastroenterol. 1990;12 (Suppl 1):S135–S138. doi: 10.1097/00004836-199001001-00023. [DOI] [PubMed] [Google Scholar]
  11. Ormand J. E., Talley N. J. Helicobacter pylori: controversies and an approach to management. Mayo Clin Proc. 1990 Mar;65(3):414–426. doi: 10.1016/s0025-6196(12)62541-5. [DOI] [PubMed] [Google Scholar]
  12. Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet. 1992 Aug;23(2):106–131. doi: 10.2165/00003088-199223020-00004. [DOI] [PubMed] [Google Scholar]
  13. Peterson W. L., Graham D. Y., Marshall B., Blaser M. J., Genta R. M., Klein P. D., Stratton C. W., Drnec J., Prokocimer P., Siepman N. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol. 1993 Nov;88(11):1860–1864. [PubMed] [Google Scholar]
  14. Peterson W. L. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991 Apr 11;324(15):1043–1048. doi: 10.1056/NEJM199104113241507. [DOI] [PubMed] [Google Scholar]
  15. Powell F. C. The skin in pregnancy--recent advances. Ir J Med Sci. 1992 Apr;161(4):99–100. doi: 10.1007/BF02983757. [DOI] [PubMed] [Google Scholar]
  16. Weil J., Bell G. D., Powell K., Morden A., Harrison G., Gant P. W., Jones P. H., Trowell J. E. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther. 1991 Jun;5(3):309–313. doi: 10.1111/j.1365-2036.1991.tb00032.x. [DOI] [PubMed] [Google Scholar]
  17. Westblom T. U., Duriex D. E. Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections. Dig Dis Sci. 1991 Jan;36(1):25–28. doi: 10.1007/BF01300082. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES